Heng Jiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Heng Jiao has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Junjie Ni
3 shared publicationsWenrui Zhao
3 shared publications- Xin Cao
Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, China
3 shared publications Xuan Huang
3 shared publicationsJiayun Hou
2 shared publications- Lijie Tan
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 30 January 2025
- Published by Elsevier in The Innovation
- Vol. 6 (4)
Novel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming
- 30 January 2025
- Published by Elsevier in The Innovation
- Vol. 6 (4)
Open AccessNovel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming
- Open Access
- 26 December 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (1) , e70148
ZSH‐2208: A novel retinoid with potent anti‐tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis
Backgroud: Oesophageal cancer ranks among the most prevalent malignant tumours globally, primarily consisting of oesophageal squamous cell carcinoma (ESCC). Cancer stem cells (CSCs) accelerate the progression ESCC via their strong self‐renewal and tumourigenic capabilities, presenting significant clinical challenges due to increased risks of recurrence and drug resistance.Methods: Our previous study has reported WYC‐209, which is capable of inducing apoptosis of CSCs in melanoma and hepatoma, but is ineffective against ESCC. Additionally, clinical studies in ESCC still lack drug candidates that effectively target CSCs. Therefore, our team developed a series of novel retinoids that target retinoic acid receptors (RARs), with enhanced potency, broader efficacy and minimised toxic side effects against CSCs. Following iterative optimisation and pharmacological validation, ZSH‐2208 was identified as the most promising candidate for effectively targeting ESCC tumour‐repopulating cells (TRCs). Mechanistic exploration revealed that ZSH‐2208 inhibits the growth of ESCC‐TRCs through modulation of the RARγ–TNFAIP3 axis. The clinical significance of the key molecule TNFAIP3 in ESCC has also been demonstrated.Results: This study introduces ZSH‐2208, a novel retinoid specifically targeting ESCC‐TRCs, which holds significant potential for clinical application in ESCC.Key points: The ESCC‐TRCs replicates the characteristics of ESCC stem cells, which are inhibited by ZSH‐2208. In vivo and in vitro experiments demonstrated that ZSH‐2208, a novel RA analogue, effectively inhibits the growth of ESCC‐TRCs through the RARγ–TNFAIP3 axis. Low levels of TNFIP3 protein may be associated with improved survival probability in ESCC patients.
- 26 December 2024
- Published by Wiley in Clinical and Translational Medicine
- Vol. 15 (1) , e70148
Open AccessZSH‐2208: A novel retinoid with potent anti‐tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis
Backgroud: Oesophageal cancer ranks among the most prevalent malignant tumours globally, primarily consisting of oesophageal squamous cell carcinoma (ESCC). Cancer stem cells (CSCs) accelerate the progression ESCC via their strong self‐renewal and tumourigenic capabilities, presenting significant clinical challenges due to increased risks of recurrence and drug resistance.Methods: Our previous study has reported WYC‐209, which is capable of inducing apoptosis of CSCs in melanoma and hepatoma, but is ineffective against ESCC. Additionally, clinical studies in ESCC still lack drug candidates that effectively target CSCs. Therefore, our team developed a series of novel retinoids that target retinoic acid receptors (RARs), with enhanced potency, broader efficacy and minimised toxic side effects against CSCs. Following iterative optimisation and pharmacological validation, ZSH‐2208 was identified as the most promising candidate for effectively targeting ESCC tumour‐repopulating cells (TRCs). Mechanistic exploration revealed that ZSH‐2208 inhibits the growth of ESCC‐TRCs through modulation of the RARγ–TNFAIP3 axis. The clinical significance of the key molecule TNFAIP3 in ESCC has also been demonstrated.Results: This study introduces ZSH‐2208, a novel retinoid specifically targeting ESCC‐TRCs, which holds significant potential for clinical application in ESCC.Key points: The ESCC‐TRCs replicates the characteristics of ESCC stem cells, which are inhibited by ZSH‐2208. In vivo and in vitro experiments demonstrated that ZSH‐2208, a novel RA analogue, effectively inhibits the growth of ESCC‐TRCs through the RARγ–TNFAIP3 axis. Low levels of TNFIP3 protein may be associated with improved survival probability in ESCC patients.
- Open Access
- 21 June 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (12) , 7852-7859
Machine learning to predict lymph node metastasis in T1 esophageal squamous cell carcinoma: a multicenter study
Background: Existing models do poorly when it comes to quantifying the risk of lymph node metastases (LNM). This study aimed to develop a machine-learning model for LNM in patients with T1 esophageal squamous cell carcinoma (ESCC). Methods and results: The study is multicenter and population based. Elastic net regression (ELR), random forest (RF), extreme gradient boosting (XGB), and a combined (ensemble) model of these were generated. The contribution to the model of each factor was calculated. The models all exhibited potent discriminating power. The elastic net regression performed best with an externally validated the area under the curve (AUC) of 0.803, whereas the NCCN guidelines identified patients with LNM with an AUC of 0.576 and the logistic model with an AUC of 0.670. The most important features were lymphatic and vascular invasion and depth of tumor invasion. Conclusions: Models created utilizing machine learning approaches had excellent performance estimating the likelihood of LNM in T1 ESCC.
- 21 June 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (12) , 7852-7859
Open AccessMachine learning to predict lymph node metastasis in T1 esophageal squamous cell carcinoma: a multicenter study
Background: Existing models do poorly when it comes to quantifying the risk of lymph node metastases (LNM). This study aimed to develop a machine-learning model for LNM in patients with T1 esophageal squamous cell carcinoma (ESCC). Methods and results: The study is multicenter and population based. Elastic net regression (ELR), random forest (RF), extreme gradient boosting (XGB), and a combined (ensemble) model of these were generated. The contribution to the model of each factor was calculated. The models all exhibited potent discriminating power. The elastic net regression performed best with an externally validated the area under the curve (AUC) of 0.803, whereas the NCCN guidelines identified patients with LNM with an AUC of 0.576 and the logistic model with an AUC of 0.670. The most important features were lymphatic and vascular invasion and depth of tumor invasion. Conclusions: Models created utilizing machine learning approaches had excellent performance estimating the likelihood of LNM in T1 ESCC.
- Open Access
- 6 December 2023
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 2 (1) , 1-14
Innovative drugs promote precision cancer therapy
Targeted therapy has fundamentally altered the diagnosis and treatment of clinical cancers. By focusing on chromosomal abnormalities and various indications of cancer, these medications have paved the way for the precise treatment of malignant tumors. In addition to markedly reversing the status quo of reliance on radiotherapy, chemotherapy, and surgery, these drugs have radically transformed the clinical treatment of advanced malignant tumors and became the leading candidates in the fight against cancer. Significant advancements in new targeted medications, including small molecules (e.g., KRASG12C inhibitors), bispecific antibodies, antibody drug conjugates, and cellular immunotherapy, are due to the advent of new technology and treatments. Notably, numerous difficulties have been encountered, although each medicine class has its own unique benefits and drawbacks. To serve as a key summary for the development of new treatment options for precision cancer medicine recently, this review aimed to summarize the most recent anti-tumor revolutionary medications with significant prospective therapeutic advantages.
- 6 December 2023
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 2 (1) , 1-14
Open AccessInnovative drugs promote precision cancer therapy
Targeted therapy has fundamentally altered the diagnosis and treatment of clinical cancers. By focusing on chromosomal abnormalities and various indications of cancer, these medications have paved the way for the precise treatment of malignant tumors. In addition to markedly reversing the status quo of reliance on radiotherapy, chemotherapy, and surgery, these drugs have radically transformed the clinical treatment of advanced malignant tumors and became the leading candidates in the fight against cancer. Significant advancements in new targeted medications, including small molecules (e.g., KRASG12C inhibitors), bispecific antibodies, antibody drug conjugates, and cellular immunotherapy, are due to the advent of new technology and treatments. Notably, numerous difficulties have been encountered, although each medicine class has its own unique benefits and drawbacks. To serve as a key summary for the development of new treatment options for precision cancer medicine recently, this review aimed to summarize the most recent anti-tumor revolutionary medications with significant prospective therapeutic advantages.
- Open Access
- 4 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (3) , 1376-1382
Carbon dioxide gas-induced pneumothorax versus one-lung ventilation in minimally invasive esophagectomy: a multicenter propensity score matching cohort study
Background: Carbon dioxide gas-induced pneumoperitoneum might be the reason for the shorter postoperative survival of patients with malignant tumors. Whether CO2 gas-induced pneumothorax has unfavorable impacts on the surgical and oncological outcomes of minimally invasive esophagectomy remains unclear. Methods: Between 2010 and 2016, a total of 998 patients with squamous cell carcinoma of the esophagus who received video-assisted surgery were registered from three large-volume medical centers. The overall survival (OS) and disease-free survival (DFS) were compared after using propensity score-matched and inverse probability-weighted methods. In addition, the tumor-relapse state was evaluated, and the relapse pattern was compared. Results: A total of 422 and 576 minimally invasive esophagectomies with intraoperative one-lung ventilation and CO2-induced pneumothorax were enrolled, respectively. The 5-year OS and DFS were similar between the CO2-induced pneumothorax (64.2% and 64.7%) and one-lung ventilation (65.3% and 62.4%) groups following propensity matching. The inverse probability weighting revealed similarly equal survival results in the two groups. The 5-year relapse rates were 35.1% and 30.6% in the one-lung ventilation and CO2-induced pneumothorax groups, respectively. Moreover, the relapse patterns were not significantly different between the two groups. Conclusion: The results of this study suggested that the use of intraoperative one-lung ventilation and CO2-induced pneumothorax have similar oncological outcomes; therefore, the two methods are both viable options in esophagectomy.
- 4 December 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (3) , 1376-1382
Open AccessCarbon dioxide gas-induced pneumothorax versus one-lung ventilation in minimally invasive esophagectomy: a multicenter propensity score matching cohort study
Background: Carbon dioxide gas-induced pneumoperitoneum might be the reason for the shorter postoperative survival of patients with malignant tumors. Whether CO2 gas-induced pneumothorax has unfavorable impacts on the surgical and oncological outcomes of minimally invasive esophagectomy remains unclear. Methods: Between 2010 and 2016, a total of 998 patients with squamous cell carcinoma of the esophagus who received video-assisted surgery were registered from three large-volume medical centers. The overall survival (OS) and disease-free survival (DFS) were compared after using propensity score-matched and inverse probability-weighted methods. In addition, the tumor-relapse state was evaluated, and the relapse pattern was compared. Results: A total of 422 and 576 minimally invasive esophagectomies with intraoperative one-lung ventilation and CO2-induced pneumothorax were enrolled, respectively. The 5-year OS and DFS were similar between the CO2-induced pneumothorax (64.2% and 64.7%) and one-lung ventilation (65.3% and 62.4%) groups following propensity matching. The inverse probability weighting revealed similarly equal survival results in the two groups. The 5-year relapse rates were 35.1% and 30.6% in the one-lung ventilation and CO2-induced pneumothorax groups, respectively. Moreover, the relapse patterns were not significantly different between the two groups. Conclusion: The results of this study suggested that the use of intraoperative one-lung ventilation and CO2-induced pneumothorax have similar oncological outcomes; therefore, the two methods are both viable options in esophagectomy.